Evolus
EOLS • NASDAQ
Evolus is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO David Moatazedi, with a market cap of $275.9M.
Market Cap$275.9M
Employees279.0
CEODavid Moatazedi
CountryUnited States of America
Healthcare
Drug Manufacturers - Specialty & Generic
Next EarningsMay 6, 2026 · In 3 weeksQ1 2026
Financials
Evolus FAQ
Common questions about Evolus
Evolus is scheduled to report earnings for Q1 2026 on May 6, 2026. Analysts estimate revenue of $72.4M.
Evolus has approximately 279 employees.